rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Azitra Inc

AZTR · NYSE American

Health CareBiotechnologyNot moving yet

AZTR stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 60.1% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
12 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0
WhoDidSharesTraded
Francisco D. SalvaPresident and CEObought50018 Mar 2026filed 20 Mar 2026
Francisco D. SalvaPresident and CEObought4,064,05018 Mar 2026filed 20 Mar 2026
Francisco D. SalvaPresident and CEObought4,064,05018 Mar 2026filed 20 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders12+5 on the quarter
New · exited6 · 1
Reported value$10.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Stonepine Capital Management, LLCnew · filed 14 Aug 202681,797,553$8.0M+81,797,553
Dauntless Investment Group, LLCadded · filed 13 Aug 202611,292,186$1.9M+11,291,186+1129118.6%
Nantahala Capital Management, LLCnew · filed 14 Aug 20262,213,613$371K+2,213,613
JANE STREET GROUP, LLCnew · filed 14 Aug 2026248,433$42K+248,433
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202695,409$16K-374,469−79.7%
CITADEL ADVISORS LLCnew · filed 14 Aug 202686,242$14K+86,242
UBS Group AGadded · filed 13 Aug 202650,481$8,481+20,276+67.1%
StoneX Group Inc.added · filed 12 Aug 202628,651$5,029+6,187+27.5%
Tower Research Capital LLC (TRC)added · filed 11 Aug 202619,500$3,272+4,415+29.3%
Corient Private Wealth LPnew · filed 12 Aug 202614,451$2,426+14,451
30 Sep 2024 – 30 Jun 2026
5912Sep 24Mar 25Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Francisco D. Salva Company insiderPresident and CEO · last 16 Jun 20261 · 0
Norm Staskey Company insiderChief Financial Officer · last 20 Apr 20262 · 0
Travis Whitfill Company insiderChief Operating Officer · last 20 Apr 20261 · 0
Barbara Ryan Company insiderDirector · last 19 Dec 20250 · 0
John R. Schroer Company insiderDirector · last 19 Dec 20250 · 0
Andrew McClary Company insiderDirector · last 21 Jun 20230 · 0
Bayer World Investments B.v. Company insider10% owner · last 21 Jun 20230 · 0
Bios Fund Iii Nt, Lp Company insider10% owner · last 21 Jun 20231 · 1
Cavu Advisors, Llc Company insider10% owner · last 21 Jun 20231 · 1

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 26 Feb 202650.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$2.1M
Free cash flowFY 2025 · to 31 Dec 2025−$11.2M

Analyst forecasts

No analyst forecasts yet.